83. Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, and Veedu RN* (2018) Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Molecular Therapy-Nucleic Acids. In Press DOI: 10.1016/j.omtn.2018.11.007.

82. Wang T, Chen C, Larcher L, Barrero RA, Veedu RN* (2018) Three Decades of Nucleic Acid Aptamer Technologies: Lessons Learned, Progress and Opportunities on Aptamer Development. Biotechnology Advances, pii: S0734-9750(18)30177-0.

81. Hassanzadeh L, Chen S, and Veedu RN* (2018) Radio-labelling of nucleic acid aptamers for highly sensitive disease-specific molecular imaging. Pharmaceuticals, 11(4). pii: E106.  
80. Wang T, Larcher L, Ma L, and Veedu RN* (2018) Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides. Molecules, 23(10). pii: E2564. 
79. Fletcher NL, Houston ZH, Simpson JD, Veedu RN* and K. J. Thurecht (2018) Designed multifunctional polymeric nanomedicines: long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials. Chemical Communications, 54(82):11538-11541. 
78. Le BT, Huges Q, Rakesh S, Baker S, Jørgensen PT, Wengel J, and Veedu RN* (2018) Unlocked nucleic acid modified primer-based enzymatic polymerization assay: Towards allele-specific genotype detection of human platelet antigens. RSC Advances, 8, 32770-32774. 
77. Macdonald J, Mandarano G, Veedu RN*, and Shigdar S. (2018) Development of transferrin receptor aptamers as drug delivery vehicles for the treatment of brain metastases.  Aptamers, 2,   15-27. 
76. Chakravarthy M, Al Shamaileh H, Huang H, Tannenberg RK, Chen S, Worrall S, Dodd PR, Veedu RN* (2018) Development of DNA aptamers targeting low-molecular-weight amyloid-β peptide aggregates in vitro. Published first online on Chemical Communication, 54, 4593-4596. 
75. Kokil G, Veedu RN, Le BT, Ramm G, and Parekh H (2018) Self-assembling asymmetric peptide-dendrimer micelles – a platform for effective and versatile in vitro nucleic acid delivery. Scientific Reports, 8, 4832-4848.
74. Macdonald J, Henri J, Roy K, Hays E, Bauer M, Veedu RN, Pouliot N, and Shigdar S (2018). EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. Cancers, 10, e19.  
73. Rahimizadeh K, AlShamaileh H, Fratini M, Chakravarthy M, Stephen M, Shigdar S, Veedu RN* (2017) Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures. Molecules, 22, 2070.
72. Le BT, Hornum M, Sharma P, Nielsen P and Veedu RN* (2017) Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2’-deoxyuridines nucleotides induce exon-skipping in vitro. RSC Advances, 7, 54542-54545.
71. Le BT, Adams AM, Fletcher S, Wilton SD, and Veedu RN* (2017) Rational design of short locked nucleic acid-modified 2’-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro. Molecular Therapy - Nucleic Acids, 9, 155–161.

70. Chakravarthy M, Chen S, Dodd PR, Veedu RN* (2017) Nucleic Acid-Based Theranostics for Tackling Alzheimer’s Disease. Theranostics, 7, 3933-3947.

69. Hughes Q*, Le BT, Gilmore G, Baker R, Veedu RN* (2017) Construction of a bivalent thrombin binding aptamer and its antidote with improved properties. Molecules, 22(10), 1770.
68. Poongavanam V, Namasivayam V, Vanangamudi M, Shamaileh H, Veedu RN, Kihlberg J, Murugan AN (2017) Integrative Approaches in HIV‐1 non-nucleoside reverse transcriptase inhibitor design. WIREs: Computational Molecular Science, e1328.

​​66. Le BT, Murayama K, Shabanpoor F, Asanuma H and Veedu RN* (2017) Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes. RSC Adv., 10, 34049-34052.

67. Chakrabarti S, Barrow CJ, Kanwar RK, Ramana V, Veedu RN, Kanwar JR (2017) Evaluation of Novel Anti-VEGF Molecules in the Animal Model of Human Lung Cancer. Aptamers and Synthetic Antibodies, 3, 74-93.

65. Al Shamaileh H and Veedu RN* (2017) Next generation nucleic acid aptamers with two base modified nucleotides improve the binding affinity and potency. ChemBioChem, 18, 1565-1567.​ 

64. Chakravarthy C, Aung-Htut MT, Le BT, Veedu RN* (2017) Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis. Scientific Reports, 7, 1613.


63. Aaldering LJ, Poongavanam P, Langkjær N, Murugan NA, Jørgensen PT, Wengel J, Veedu RN* (2017) Development of an efficient G-quadruplex stabilized thrombin binding aptamer containing 3-carbon spacer molecule. ChemBioChem, 18, 755-763.

​62. Chen S, Le BT, Rahimizadeh K, Shaikh K, Mohal N, Veedu RN* (2016) Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide. Molecules, 21, 1582.

61. Le BT, Chen S, Abramov M, Herdewijn P, Veedu RN* (2016) Evaluation of Anhydrohexitol nucleic acid, Cyclohexenyl nucleic acid and D-Altritol nucleic acid-modified 2’-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro. Chemical Communication, 52, 13467-13470.

60. Le BT, Filichev VV, Veedu RN* (2016) Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping in vitro. RSC Advances, 6, 95169-9517.

59. Veedu RN, Aptamers: Tools for Targeted Nanotherapy and Molecular Imaging, Pan Stanford Publishing Pte Ltd, CRC Press, Singapore, 2016. (http://www.amazon.com/Aptamers-Tools-Nanotherapy-Molecular-Imaging/dp/9814669830)

58. Lipi F, Chen S, Chakravarthy M, Rakesh S, Veedu RN* (2016) In vitro evolution of chemically-modified nucleic acid aptamers: Pros & cons, and comprehensive selection strategies. RNA Biology, 13, 1232-1245.

57. Aaldering LJ, Krishnan S, Fletcher S, Wilton S, Veedu RN* in Aptamers: Tools for Targeted Nanotherapy and Molecular Imaging, ed. Veedu RN, Pan Stanford Publishing, Singapore, 2016, pp. 151-167.  

56. Veedu RN* (2016) Nucleic Acids, Australian Journal of Chemistry, 69, 1071-1072.

55. Chaudhary R, Roy K, Kanwar RK, Veedu RN, Krishnakumar S, Cheung CHA, Verma AK, Kanwar JR* (2016) E-Cadherin Aptamer-Conjugated Delivery of Doxorubicin for Targeted Inhibition of Prostate Cancer Cells. Australian Journal of Chemistry, 69, 1108-1116.

54. Le BT, Veedu RN, Fletcher S, Wilton SD* (2016) Antisense oligonucleotide development for the treatment of muscular dystrophies. Expert Opinion on Orphan Drugs, 4, 139-152.

53. Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Neerati P, Leth-Larsen R, Petersen M, Marusic M, Plavec J, Wengel J, Veedu RN* (2015) Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition. Chemical Communications, 51, 9499-9502.

52. Veedu RN* (2015) Editorial: medicinal chemistry of aptamers. Current Topics in Medicinal Chemistry, 15, 1065.

51. Kokil GR, Veedu RN*, Ramm GA, Prins JB, Parekh HS* (2015) Type 2 Diabetes Mellitus: Limitations of Conventional Therapies and Intervention with Nucleic Acid-Based Therapeutics. Chemical Reviews, 115, 4719–4743.

50. Aaldering LJ, Tayeb H, Krishnan S, Fletcher S, Wilton SD, Veedu RN* (2015) Smart Functional Nucleic Acid Chimeras: Enabling Tissue Specific RNA Targeting Therapy. RNA Biology, 12, 412-425.

49. Wilton SD*, Veedu RN, Fletcher S (2015) The Emperor’s new dystrophin: finding sense in the noise. Trends in Molecular Medicine, 21, 417-26.

48. Roy K, Kanwar RK, Antonio Cheung CH, Lee Fleming C, Veedu RN, et al. (2015) Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Advances, 5, 29008-29016.

47. Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, et al. (2015) Nucleic Acid-Based Aptamers: Applications, Development And Clinical Trials. Current Medicinal Chemistry, 22, 2539-2557.

46. Wentrup C, Kvaskoff D, Veedu RN (2015) Comments on photochromism of 3-(3-pyridyl) sydnone and 4-alkenylsydnones. Journal of Photochemistry and Photobiology A: Chemistry, 298, 62-63.

45. Veedu RN, Adams A, Fletcher S, Shastri A, Wengel J, Wilton S (2015) Locked nucleic acid-modified antisense oligonucleotides for enhanced exon skipping in duchenne muscular dystrophy. Journal of Gene Medicine, 17, 193-194.

44. Sriramoju B, Kanwar R, Veedu RN, Kanwar JR (2015) Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases. Current Topic in Medicinal Chemistry, 15, 1115-24.

43. Poongavanam V, Madala PK, Højland T, Veedu RN (2014) Computational Investigation of Locked Nucleic Acid (LNA) nucleotides in the Active Sites of DNA Polymerases by Molecular Docking Simulations. PLOS ONE, 9, e102126.

42. Kim KT, Veedu RN, Seo YJ, Kim BH (2014) Design of Quencher-free Molecular Beacons for Probing CAG Repeat Oligonucleotides. Chemical Communications, 50, 1561-1563.

41. Veedu RN, Kvaskoff D, Wentrup C (2013) Sydnone Photochemistry. Direct Observation of Earlâs Bicyclic Lactone Valence Isomers (Oxadiazabicyclo[2.1.0]pentanones), Formation of Carbodiimides, Reaction Mechanism, and Photochromism, Australian Journal of Chemistry, 67, 457-68.

40. Marušič M, Veedu RN, Wengel J, Plavec J (2013) G-rich VEGF aptamer with locked and unlocked nucleic acid modifications exhibits a unique G-quadruplex fold. Nucleic Acids Research, 41, 9524-36.

39. Coles DJ, Rolfe BE, Boase NRB, Veedu RN, Thurecht KJ (2013) Aptamer-targeted hyperbranched polymers: Towards greater specificity for tumours in vivo. Chemical Communications, 49, 3836-3838.


38. Gurudevan S, Kanwar R, Veedu RN, Sasidharan S, Kennedy RL, Kanwar JR (2013) Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer. Current Gene Therapy, 13, 322-34.

37. Morihiro K, Kodama T, Tefu K, Moai Y, Veedu RN, Obika S (2013) Selenomethylene-Locked Nucleic Acid (SeLNA) Enables Reversible Hybridization in Response to Redox Changes. Angewandte Chemie International Edition, 52, 5074-5078.

36. Tannenberg R, Shamaileh HA, Lauridsen LH, Kanwar JR, Dodd PR, Veedu RN (2013) Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology. Current Alzheimer Research, 10, 442-448.

35. Dawar S, Singh N, Kanwar R, Kennedy RL, Veedu RN, Zhou SF, Krishnakumar S, Hazra S, Sasidharan S, Kanwar JR (2013) Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discovery Today, 18, 1292-300.

34. Lauridsen LH, Shamaileh LH, Edwards SL, Taran E, Veedu RN (2012) Rapid One-Step Selection Method for Generating Nucleic Acid Aptamers: Development of a DNA aptamer against Alpha-Bungarotoxin. PLOS ONE, 7, e41702.

33. Wheeler M, Chardon A, Goubet A, Morihiro K, Tsan SY, Edwards SL, Kodama T, Obika S, Veedu RN (2012) Synthesis of Selenomethylene-Locked Nucleic Acid (SeLNA)-Modified Oligonucleotides by Polymerases. Chemical Communications, 48, 11020-11022.

32. Goubet A, Chardon A, Kumar P, Sharma PK, Veedu RN (2012) Synthesis of DNA oligonucleotides containing C5-ethynylbenzenesulfonamide-modified nucleotides (EBNA) by polymerases towards the construction of base functionalized nucleic acids. Bioorganic & Medicinal Chemistry Letters, 23, 761-763.

31. Dubois C, Campbell MM, Edwards SL, Wengel J, Veedu RN (2012) Stepping Towards Highly Flexible Aptamers: Enzymatic Recognition Studies of Unlocked Nucleic Acid Nucleotides. Chemical Communications, 48, 5503-5505.

30. Lauridsen LH, Veedu RN (2012) Nucleic Acid Aptamers against Bio-toxins: A New Paradigm towards the Treatment and Diagnostic Approach. Nucleic Acid Therapeutics, 22, 

29. Crouzier L, Dubois C, Wengel J, Veedu RN (2012) Cleavage and Protection of Locked Nucleic Acid-Modified DNA by Restriction Endonucleases. Bioorganic & Medicinal Chemistry Letters, 22, 4836-4838.

28. Crouzier L, Dubois C, Edwards SL, Lauridsen LH, Wengel J, Veedu RN (2012) Efficient Reverse Transcription using Locked Nucleic Acid Nucleotides towards the Evolution of Nuclease Resistant RNA Aptamers. PLOS ONE, 7, e35990.

27. Lauridsen LH, Rothnagel JA, Veedu RN (2012) Enzymatic Recognition of 2'-Modified Ribonucleoside-5'-triphosphates: Towards the Evolution of Versatile Aptamers. ChemBioChem, 13, 19-25.

26. Johannsen MW, Veedu RN, Madsen AS, Wengel J (2012) Enzymatic Polymerisation Involving 2'-amino-LNA Nucleotides. Bioorganic & Medicinal Chemistry Letters, 22, 3522–3526.

25. Doessing H, Hansen LH, Veedu RN, Wengel J, Vester B (2012) Amplification and re-generation of LNA-modified libraries. Molecules, 17, 13087-13097.

24. Højland T, Veedu RN, Vester B, Wengel J (2012) Enzymatic synthesis of DNA strands containing a-L-LNA (a-L-configured locked nucleic acid) thymine nucleotides. Artificial DNA: PNA & XNA, 3, 1-8.

23. Bernhardt P, Kvaskoff D, Veedu RN, Wentrup C (2012) Polymorphism in 3-Pyridylsydnone: Preparative and Structural Aspects. Australian Journal of Chemistry, 65, 376–380.

22. Veedu RN, Wengel J (2012) Therapeutic Applications of Locked Nucleic Acid nucleotides, In "Chemistry and Biology of Artificial Nucleic Acids" Eds. Martin Egli and Piet Herdewijn, Wiley-VCH Publishers, Weinheim, Germany, ISBN: 978-3-90639-067-3, 159-165p

21. Pasternak K, Pasternak A, Kumar P, Veedu RN, Wengel J (2011) Photoligation of self-assembled DNA constructs containing anthracene-functionalized 2'-amino-LNA monomers. Bioorganic & Medicinal Chemistry, 19, 7407-7415.

20. Veedu RN, Wengel J (2011) Locked Nucleic Acid Oligonucleotides towards Clinical Applications, In "Medicinal Chemistry of Nucleic Acids" Eds. Li-he Zhang, Zhen Xi, and Jyoti Chattopadhyaya, John Wiley & Sons, Inc. of 111 River Street, Hoboken, New Jersey 07030-5774, 335pp.

19. Veedu RN, Burri HV, Kumar P, Sharma PK, Hrdlicka PJ, Vester B, Wengel J (2010) Polymerase-Directed Synthesis of C5-Functionalized Nucleic Acids. Bioorganic & Medicinal Chemistry Letters, 20, 6565-6568.

18. Veedu RN, Wengel J (2010) Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications. Chemistry & Biodiversity, 7, 536-542.

17. Veedu RN, Vester B, Wengel J (2010) Polymerase directed incorporation studies of LNA-G 5’-triphophates and primer extension involving all four LNA nucleotides. New Journal of Chemistry, 34, 77.